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Abstract
Osmotic diarrhea and abdominal pain in humans are oftentimes associated with carbohydrate malabsorption in the
small intestine due to loss of function of microvillar disaccharidases. Disaccharidases are crucial for the digestion
and the subsequent absorption of carbohydrates. This review focuses on sucrase-isomaltase as the most abundant
intestinal disaccharidase and the primary or induced pathological conditions that affect its physiological function.
Congenital defects are primary factors which directly influence the transport and function of sucrase-isomaltase in a
healthy epithelium. Based on the mutation type and the pattern of inheritance, a mutation in the sucrase-isomaltase
gene may exert a variety of symptoms ranging from mild to severe. However, structure and function of wild type
sucrase-isomaltase can be also affected by secondary factors which influence its structure and function either specifically
via certain inhibitors and therapeutic agents or generally as a part of intestinal pathogenesis, for example in the
inflammatory responses. Diagnosis of sucrase-isomaltase deficiency and discriminating it from other gastrointestinal
intolerances can be latent in the patients because of common symptoms observed in all of these cases.
Here, we summarize the disorders that implicate the digestive function of sucrase-isomaltase as well as the diagnostic
and therapeutic strategies utilized to restore normal intestinal function.
Keywords: Sucrase-isomaltase, Congenital sucrase-isomaltase deficiency, Carbohydrate maldigestion, Gastrointestinal
intolerance, Inflammation, Gut microbiota
Dietary carbohydrates as human energy source
Carbohydrates are one of the vital mammalian nutrients
which have been increasingly consumed by human popula-
tions since the agricultural revolution and serve as import-
ant calorie sources [1]. Dietary carbohydrates mainly
include sucrose and a variety of plant starches which are
composed of different α-linked sugars. Sugar transporters
in the intestine are only capable of transporting monosac-
charides. Therefore, accessibility of higher carbohydrates to
the human body as energy sources necessitates their hy-
drolysis to simple monosaccharides. Starch digestion is ini-
tiated by salivary and later pancreatic α-amylases that
break it down to smaller units composed of two, three, or
four sugar residues. The final step of starch digestion takes
place in the intestinal lumen by α-glucosidases that are lo-
calized on the brush border membrane (BBM) of the intes-
tinal epithelium. This family of digestive enzymes includes
sucrase-isomaltase (SI), maltase-glucoamylase (MGAM)
and trehalase [2]. Due to its high abundance and its wide
substrate specificity in hydrolyzing α-1,2, α-1,6, and α-1,4
glucosidic bonds, human SI is responsible for almost all su-
crase activity and about 60 to 80 % of maltase activity in
the intestinal lumen [3].
Physiological and functional requirements for
carbohydrate processing
Before SI can fulfill its hydrolytic function in the intestinal
lumen, it needs to be intracellularly processed and prop-
erly transported to the BBM surface of the epithelial cells.
Both active subunits are then oriented into the intestinal
lumen [4]. SI is a type II membrane glycoprotein. It is N-
glycosylated in the endoplasmic reticulum (ER) and then
transported to the Golgi apparatus where it is complex N-
and O-glycosylated. Both of these modifications have a
crucial role in the folding, acquisition of the functional
capacity, and later appropriate sorting of the SI molecules
to the BBM [5]. The latter process is mediated via associ-
ation of SI molecules with cholesterol- and sphingolipid-
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enriched membrane microdomains, known as lipid rafts
[6], in the trans-Golgi network for which proper O-
glycosylation is essentially required [5].
Etiology and common symptoms of intestinal
disorders by SI malfunction
The clinical presentation of intestinal disorders caused by
SI malfunction is oftentimes an osmotic-fermentative diar-
rhea upon ingestion of carbohydrates associated with
symptoms such as vomiting, flatulence and abdominal
pain [2]. An increased osmotic load due to unabsorbed
carbohydrates in the intestinal lumen and colon causes a
flow of water and electrolytes into the lumen, thus affect-
ing the gut motility by accelerating the small intestinal
transit leading to chronic diarrhea. Other symptoms like
gaseous abdominal distension, flatulence, and cramps are
caused by bacterial fermentation of unabsorbed carbohy-
drates which additionally increase the osmotic pressure
[3]. The accelerated transit further increases the degree of
maldigestion of starch and monosaccharides and also af-
fects the absorption of other nutrients, leading to a risk of
malnutrition and failure to thrive in patients [7]. Add-
itional factors contributing to the onset of disease are the
quantity of ingested carbohydrates and other food compo-
nents, the rate of gastric emptying, the metabolic activity
of fermenting bacteria, the degree of the residual enzyme
activity of SI and other intestinal disaccharidases as well
as coexisting intestinal disorders or inflammation.
SI deficiencies can be categorized as (a) primary or con-
genital SI deficiencies which are caused by genetic alter-
ations in the SI gene and are already present at birth and
(b) induced or secondary SI deficiencies which occur later
in life and are mediated by environmental factors or arise
as a consequence of other genetic deficiencies which nega-
tively influence the intestinal physiology in general and SI
function in particular.
Congenital sucrase-isomaltase deficiency
Congenital sucrase-isomaltase deficiency (CSID) is a
genetically determined primary defect of SI which is as-
sociated with carbohydrate malabsorption [3]. CSID is
elicited by single-nucleotide polymorphism in the SI
gene leading to single amino acid exchanges in the pro-
tein. These mutations can affect each of the SI domains
but do not per se lead to complete lack of SI or its ac-
tivities in the BBM essentially. Requirements for proper
functioning of SI, including intact glycosylation and
folding, correct intracellular trafficking, association
with lipid rafts and apical delivery to the cell surface
are directly or indirectly correlated to each other and
are initially regulated at the amino acid sequence level
[5]. Malfolding of SI mutants may affect the trafficking or
even lead to degradation via the endoplasmic reticulum-
associated protein degradation (ERAD) pathway [8]. Other
mutants of SI proteins with impaired or delayed trafficking
though with normal hydrolytic properties cannot fulfill
their physiological functions due to mislocalization. Muta-
tions can affect one or more of these features depending
on their position within SI. Biochemical, cellular and func-
tional analyses of a number of SI mutations constituted the
basis for a classification of these mutants into seven pheno-
types depending on the intracellular localization and func-
tion of SI [9] (Table 1). Phenotypes I and II include
mutations which are blocked in the ER (I) or ER-Golgi
intermediate compartment (ERGIC) and cis-Golgi com-
partments (II). A normal trafficking but absent enzymatic
function characterizes mutations of phenotype III. SI mu-
tants grouped in phenotype IV exhibit sorting defects to
the microvillar membranes and that of phenotypes V and
VI are intracellularly cleaved. Phenotype VII is character-
ized by altered folding, increased turnover rate, and partial
missorting [9]. The most common mutations with an
estimated frequency of 83 % in European descendants
with CSID are Gly1073Asp, Val577Gly, Phe1745Cys
and Arg1124Stop [10]. These mutations are intracellu-
larly blocked in the ER and belong to phenotype I. A
decisive factor in occurrence and severity of CSID is
whether only one or both alleles of the gene are af-
fected by mutations. Initially reported cases of CSID
that were characterized by genetic sequencing mostly
illustrated homozygote or compound heterozygote
patterns of inheritance [11]. In the recent years, feasi-
bility of gene sequencing has led to identification of
many novel cases of CSID, among which also simple
Table 1 Phenotypic categorization of SI mutants
Phenotype of SI mutants Transport and function
I Blocked in the ER, enzymatically inactive
II Blocked in the ER, ER-Golgi intermediate compartment, and cis-Golgi, inactive
III Normal intracellular protein transport but absent activities
IV Sorting defects, enzymatically active
V Intracellular proteolytic cleavage and degradation of sucrase, normal transport and partial activity
VI Intracellular proteolytic cleavage and secretion of SI, complete activity
VII Altered trafficking and increased turnover rate, partially active
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heterozygote subjects with only one affected allele
exist [10].
Based on the mutation type, the combinatorial effects of
two mutations or of one mutation with the wild-type pro-
tein can set the course of the disease and generate a mild
to severe gradient of symptoms. The CSID symptoms are
similar to those of other intestinal diseases and oftentimes
lead to misdiagnosis or late diagnosis after childhood [3].
The high phenotypic diversity, genetic heterogeneity and
common symptoms with other intestinal diseases lead to
the assumption that CSID is more common than what
has been initially estimated.
Secondary deficiencies of SI activity
The major types of secondary or induced SI deficiencies
can be categorized into three main groups: (a) those that
are induced by physical injuries to the intestine and dis-
rupt the intestinal epithelium, (b) those that are caused via
inhibitory function of some dietary components or thera-
peutic agents on the function of SI, and (c) those that are
connected to infections or autoimmune disorders. In what
follows, we will discuss the role of therapeutic agents and
autoimmune disorders on SI deficiency in more details.
i) Therapeutic agents that inhibit the SI function
There exist a large number of reports on the natural or
synthetic compounds for deliberate reduction of disaccha-
ridase activities in the intestine in order to control obesity
or diabetic conditions. Apart from such compounds, our
focus here is on medications that induce SI inhibition as
an adverse effect. For example, N-butyldeoxynojirimycin
(miglustat) that is used for treatment of lysosomal storage
diseases can heavily inhibit SI and thus result in gastro-
intestinal symptoms in the majority of the patients [12].
Codeine as a pain medication and ranitidine with antihis-
tamine effect can also inhibit sucrase activity in the intes-
tine [13, 14]. Furthermore, several herbal folk remedies,
especially those with polyphenolic components, also exert
an inhibitory effect on SI [15].
ii) Role of gut autoimmune disorders in SI deficiency
Intestinal lymphatic tissue, named gut-associated lymph-
oid tissue (GALT), is known to be the largest compartment
of the immune system. The intestinal tract is highly and
directly exposed to foreign material through the ingestion
of food. On the other hand, the commensal bacteria in the
colon, the gut microbiota, can be differently modulated by
diet or physiological conditions of the gut and can con-
sequently influence the gut immune system [16]. All of
these factors have rendered the gut tissue highly sus-
ceptible to autoimmune disorders and the subsequent
tissue pathogenesis.
iii) Celiac disease
Celiac disease (CD) is one of the most common causes
of chronic intestinal malabsorption and leads to occur-
rence of conventional gastrointestinal symptoms as a re-
sult of villus atrophy [17]. The disease is an autoimmune
disorder that is triggered by hypersensitivity to ingested
gliadins from wheat and other cereals [18]. The frequency
of this disease can be up to 3 % in the different popula-
tions, but this ratio was detected to be as high as 11 %
among patients with type 1 diabetes mellitus [19]. As a
direct consequence of villus atrophy in CD, the expression
and activity levels of intestinal disaccharidases including
SI are significantly reduced. Therefore, SI expression has
been used as an indicator to diagnose and later evaluate
the physiological response to different treatments of the
patients [20, 21]. Disaccharidase deficiencies can be also
detected in CD patients with intact villi, which may repre-
sent latent development of CD [22].
iv) Inflammatory bowel disease
Inflammatory bowel disease (IBD) which is mostly diag-
nosed in the forms of Crohn’s disease and ulcerative colitis
is an autoimmune disease in which imbalance between
anti- and pro-inflammatory cytokines results in severe
organ pathology and loss of barrier function in the intes-
tinal tissue [23]. Induced colitis in animal models revealed
local colon inflammation affecting the intestinal function
in the ileal and jejunal areas and resulting in loss of SI ex-
pression and activity [24]. Besides that, the existing SI
molecules are not properly expressed at the apical cell sur-
face and reveal a predominant intracellular localization
[25]. In a Caco-2 cell model of the intestinal epithelium,
treatment with interleukin 6 and interferon gamma led to
a significant decrease in the biosynthesis of SI [26]. There-
fore, it can be concluded that SI deficiency in IBD patients
occurs as an indirect effect of tissue injury alongside the
direct effects of the inflammatory cytokines on the expres-
sion and function of SI.
v) Human immunodeficiency virus infection
Gastrointestinal intolerances are common symptoms in
human immunodeficiency virus (HIV)-infected patients
[27]. In contrast to healthy HIV-positive individuals, severe
SI and lactase-phlorizin hydrolase deficiencies are identified
in most of the jejunal specimens from patients with ac-
quired immune deficiency syndrome (AIDS) [27]. The
gastrointestinal symptoms are associated with rapid small
bowel transit [28] and are not influenced by anti-retroviral
therapy [29]. Infection of rhesus monkeys with simian im-
munodeficiency virus (SIV) is a known experimental animal
model for HIV. As shown in this model, gut-associated
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lymphoid tissue is one of the first targets of SIV infection
[30]. Negative regulation of the IL-6-STAT3 pathway
seems to be responsible for the persistent inflamma-
tion in the jejunum and colon of these animals [31].
Development of disaccharidase deficiencies in later
stages of HIV infection can be also associated with im-
munodeficiency or infection with opportunistic enter-
opathogens [30].
vi) Giardiasis
Giardiasis can also trigger autoimmune responses that
cause mucosal alterations in the intestine. In this case, the
microvilli are shortened and the level of SI as well as other
disaccharidases is reduced in a direct relation to the num-
ber of parasites [32]. In a study using isolated T cells from
infected mice, Scott et al. could show that the CD8(+) T
cells mediate the loss of brush border area and reduce di-
saccharidase levels in the uninfected recipient mice [33].
vii) Other secondary factors influencing the SI function
Additionally reported factors influencing the function of
SI and thereby triggering carbohydrate malabsorption
symptoms are summarized in this part. Rotavirus infections
or acute Yersinia enterocolitica infections affect the micro-
villar cytoskeleton structure of the intestinal enterocytes
and thereby cause a decreased disaccharidase expression
and function at the BBM [34, 35]. Also, the Shiga toxin
(Stx) is reported to affect SI function by inhibiting the
synthesis of BBM proteins as well as damaging the in-
testinal epithelium directly [36]. If the intestinal tissue
is subjected to ischemia with blocked or decreased
blood flow, a decrease in disaccharidase activities can
be detected [37]. Chronic psychological stresses as well
as deficiencies of iron and vitamin A are other factors
that are associated with loss of the sucrase activity in
the intestine [38–41].
Diagnosis
The gold standard for the diagnosis of intestinal disorders
associated with carbohydrate malabsorption due to pri-
mary or secondary defects in SI are endoscopic small
bowel biopsies and assessment of disaccharidase activ-
ities exvivo. The additional histological examination of the
intestinal biopsy specimen allows distinguishing between
primary and secondary disaccharidase disorders [42]. In
primary disorders, normal intestinal morphology con-
comitant with reduced enzymatic activities are expected
while secondary disorders oftentimes go along with an im-
paired intestinal morphology. Confocal laser endomicro-
scopy (CLE) is a novel endoscopic technique to visualize
the intestinal morphology in vivo [43]. A non-invasive but
not always reliable diagnostic approach is the hydrogen
Fig. 1 Multifactorial causes of primary or secondary sucrase-isomaltase deficiencies. The SI function in cleaving carbohydrates depends on the correct
transport of the enzymatically competent protein to the BBM. This process occurs via association of SI with lipid rafts in the trans-Golgi network vesicles
that are transported to the BBM along the actin cytoskeleton. The digestive capacity of SI can be affected by primary genetic mutations that target the
SI gene. On the other hand, environmental factors can also influence expression and function of SI. The induced or secondary effects on the SI function
can be elicited by altered epithelial cell integrity or the cytoskeletal organization of the enterocytes as well as changes in the healthy protective microflora.
In some cases, the structure and function of SI can be directly influenced by certain therapeutics or dietary components. Together, alterations
in the intestinal physiology triggered for example by inflammation can exert adverse effects on the trafficking and function of SI. The maldigested
carbohydrates will in turn moderate the gut microbiota differently from healthy conditions and may render subsequent negative influences on the
intestinal physiology
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breath test that measures the exhaled H2 levels produced
by bacterial fermentation after ingestion of a test carbohy-
drate. An increased hydrogen of more than 20 part per
million is considered to indicate carbohydrate malabsorp-
tion [44]. Mutations in the SI gene causing CSID can be
identified by genetic screenings using saliva or blood of
patients. Prior to the mentioned diagnostic methods, a diet-
ary assessment by food exclusion and observation of symp-
tom improvement can give first hints to carbohydrate
malabsorption. Blood and fecal tests can additionally pro-
vide information on possible intestinal inflammation [45].
Therapy
There are different treatment options of disaccharide mal-
absorption due to SI malfunction. One possibility is dietary
management by a life-long sucrose- and starch-restricted
diet adapted to the requirements of the patient. A good al-
ternative to the avoidance of malabsorbed sugars, which
may not be easy especially for children, is the enzyme re-
placement therapy to compensate the malfunction of SI.
Sacrosidase or invertase (Sucraid) which is a liquid prepar-
ation from Saccharomyces cerevisiae is frequently used as
therapy for intestinal disorders associated with carbohy-
drate malabsorption [3]. Prevention and treatment of sec-
ondary intestinal disorders with indirect influence on the
SI function can be achieved by the ingestion of probiotics
which are beneficial microorganisms to the human health
[46]. The normal intestinal flora or microbiota provides an
effective barrier against pathogenic microorganism. Dis-
ruption of this healthy microflora can increase the suscep-
tibility for pathogenic infections which may in turn affect
the BBM and thereby negatively influence the SI function.
Intake of prebiotics (poorly digestible carbohydrates) and
probiotics supports the maintenance or reestablishment of
a healthy gut microflora [46, 47].
Conclusions
SI is a unique enzyme of the intestinal epithelium due to
its high prevalence and its wide substrate specificity for di-
gestion of different dietary carbohydrates. Therefore, defi-
ciencies in the SI function can substantially disrupt the
intestinal physiology, a fact associated with gastrointestinal
symptoms, weight loss, and immunological disorders me-
diated by altered gut microbiota. On the other hand,
organ pathologies that generally influence the intestinal
tissue, such as IBD or specific inhibition of SI by thera-
peutic or dietary substances can substantially reduce the
capacity of the intestinal lumen in SI activity (Fig. 1). If
not treated, the outcome of this condition can result in
progressive and life-threatening gastrointestinal symp-
toms. Therefore, it is legitimate to consider a major role
for the proper function of SI in the maintenance of the in-
testinal physiology.
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